Your browser doesn't support javascript.
loading
Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink.
Kenigsberg, Tat'Yana A; Hanson, Kayla E; Klein, Nicola P; Zerbo, Ousseny; Goddard, Kristin; Xu, Stanley; Yih, W Katherine; Irving, Stephanie A; Hurley, Laura P; Glanz, Jason M; Kaiser, Robyn; Jackson, Lisa A; Weintraub, Eric S.
Affiliation
  • Kenigsberg TA; Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: ynf1@cdc.gov.
  • Hanson KE; Marshfield Clinic Research Institute, Marshfield, WI, USA.
  • Klein NP; Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California, Oakland, CA, USA.
  • Zerbo O; Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California, Oakland, CA, USA.
  • Goddard K; Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California, Oakland, CA, USA.
  • Xu S; Kaiser Permanente Southern California, Pasadena, CA, USA.
  • Yih WK; Harvard Pilgrim Health Care Institute, Boston, MA, USA.
  • Irving SA; Kaiser Permanente Center for Health Research, Portland, OR, USA.
  • Hurley LP; Denver Health, Denver, CO, USA.
  • Glanz JM; Institute for Health Research, Kaiser Permanente, Denver, CO, USA.
  • Kaiser R; HealthPartners Institute, Minneapolis, MN, USA.
  • Jackson LA; Kaiser Permanente Washington Research Institute, Seattle, WA, USA.
  • Weintraub ES; Centers for Disease Control and Prevention, Atlanta, GA, USA.
Vaccine ; 41(32): 4658-4665, 2023 07 19.
Article in En | MEDLINE | ID: mdl-37344264
INTRODUCTION: Safety data on simultaneous vaccination (SV) with primary series monovalent COVID-19 vaccines and other vaccines are limited. We describe SV with primary series COVID-19 vaccines and assess 23 pre-specified health outcomes following SV among persons aged ≥5 years in the Vaccine Safety Datalink (VSD). METHODS: We utilized VSD's COVID-19 vaccine surveillance data from December 11, 2020-May 21, 2022. Analyses assessed frequency of SV. Rate ratios (RRs) were estimated by Poisson regression when the number of outcomes was ≥5 across both doses, comparing outcome rates between COVID-19 vaccinees receiving SV and COVID-19 vaccinees receiving no SV in the 1-21 days following COVID-19 vaccine dose 1 and 1-42 days following dose 2 by SV type received ("All SV", "Influenza SV", "Non-influenza SV"). RESULTS: SV with COVID-19 vaccines was not common practice (dose 1: 0.7 % of 8,455,037 persons, dose 2: 0.3 % of 7,787,013 persons). The most frequent simultaneous vaccines were influenza, HPV, Tdap, and meningococcal. Outcomes following SV with COVID-19 vaccines were rare (total of 56 outcomes observed after dose 1 and dose 2). Overall rate of outcomes among COVID-19 vaccinees who received SV was not statistically significantly different than the rate among those who did not receive SV (6.5 vs. 6.8 per 10,000 persons). Statistically significant elevated RRs were observed for appendicitis (2.09; 95 % CI, 1.06-4.13) and convulsions/seizures (2.78; 95 % CI, 1.10-7.06) in the "All SV" group following dose 1, and for Bell's palsy (2.82; 95 % CI, 1.14-6.97) in the "Influenza SV" group following dose 2. CONCLUSION: Combined pre-specified health outcomes observed among persons who received SV with COVID-19 vaccine were rare and not statistically significantly different compared to persons who did not receive SV with COVID-19 vaccine. Statistically significant adjusted rate ratios were observed for some individual outcomes, but the number of outcomes was small and there was no adjustment for multiple testing.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Influenza Vaccines / Influenza, Human / COVID-19 Limits: Humans Language: En Journal: Vaccine Year: 2023 Type: Article

Full text: 1 Database: MEDLINE Main subject: Influenza Vaccines / Influenza, Human / COVID-19 Limits: Humans Language: En Journal: Vaccine Year: 2023 Type: Article